DelveInsight’s “Dysmenorrhea Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dysmenorrhea market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Dysmenorrhea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dysmenorrhea Market Insights
Dysmenorrhea Overview
Painful menstrual periods in medical term are described as Dysmenorrhea, which is often called as“ menstrual cramps” in simpler terms. Dysmenorrhea can be classified into two types: Primary Dysmenorrhea and Secondary Dysmenorrhea.
Some of the key facts of the Dysmenorrhea Market Report:
- The Dysmenorrhea market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In the year 2019, the total prevalent case of Dysmenorrhea was 134,928,831 cases in the 7MM. The United States, in 2019, accounted for nearly 43% of the total 7MM cases
- Among the EU-5 countries, the highest number of cases of Dysmenorrhea were in Germany, i.e. 13,162,395 cases in the year 2019, which is estimated to rise by the year 2032.
- Key Dysmenorrhea Companies: Myovant Sciences GmbH, Takeda, ObsEva SA, Fuji Pharma’s, Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson & Johnson, Alvogen, and others
- Key Dysmenorrhea Therapies: Relugolix, Yselty, FSN-013, and others
- The Dysmenorrhea epidemiology based on severity analyzed that more than two-thirds of dysmenorrhea patients reported moderate-to-severe pain
Get a Free sample for the Dysmenorrhea Market Report –
https://www.delveinsight.com/sample-request/dysmenorrhea-market
Key benefits of the Dysmenorrhea Market report:
- Dysmenorrhea market report covers a descriptive overview and comprehensive insight of the Dysmenorrhea Epidemiology and Dysmenorrhea market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Dysmenorrhea market report provides insights on the current and emerging therapies.
- Dysmenorrhea market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Dysmenorrhea market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Dysmenorrhea market.
Download the report to understand which factors are driving Dysmenorrhea epidemiology trends @ Dysmenorrhea Epidemiological Insights
Dysmenorrhea Market
The dynamics of the Dysmenorrhea market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Dysmenorrhea Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dysmenorrhea Epidemiology Segmentation:
The Dysmenorrhea market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Dysmenorrhea
- Prevalent Cases of Dysmenorrhea by severity
- Gender-specific Prevalence of Dysmenorrhea
- Diagnosed Cases of Episodic and Chronic Dysmenorrhea
Dysmenorrhea Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dysmenorrhea market or expected to get launched during the study period. The analysis covers Dysmenorrhea market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dysmenorrhea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Dysmenorrhea market share @ Dysmenorrhea market forecast
Dysmenorrhea Therapies and Key Companies
- Relugolix: Myovant Sciences GmbH/ Takeda
- Yselty: ObsEva SA
- FSN-013: Fuji Pharma’s
Dysmenorrhea Market Drivers
- Increasing prevalence owing to increase in awareness and changing lifestyle
- Emerging Landscape with promising early efficacy signals
Scope of the Dysmenorrhea Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Dysmenorrhea Companies: Myovant Sciences GmbH, Takeda, ObsEva SA, Fuji Pharma’s, Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson & Johnson, Alvogen, and others
- Key Dysmenorrhea Therapies: Relugolix, Yselty, FSN-013, and others
- Dysmenorrhea Therapeutic Assessment: Dysmenorrhea current marketed and Dysmenorrhea emerging therapies
- Dysmenorrhea Market Dynamics: Dysmenorrhea market drivers and Dysmenorrhea market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Dysmenorrhea Unmet Needs, KOL’s views, Analyst’s views, Dysmenorrhea Market Access and Reimbursement
Dysmenorrhea Market Barriers
- Limitations of the current therapies such as side effects and mediocre efficacy
- The anticipated increasing use of generics
Table of Contents
1. Dysmenorrhea Market Report Introduction
2. Executive Summary for Dysmenorrhea
3. SWOT analysis of Dysmenorrhea
4. Dysmenorrhea Patient Share (%) Overview at a Glance
5. Dysmenorrhea Market Overview at a Glance
6. Dysmenorrhea Disease Background and Overview
7. Dysmenorrhea Epidemiology and Patient Population
8. Country-Specific Patient Population of Dysmenorrhea
9. Dysmenorrhea Current Treatment and Medical Practices
10. Dysmenorrhea Unmet Needs
11. Dysmenorrhea Emerging Therapies
12. Dysmenorrhea Market Outlook
13. Country-Wise Dysmenorrhea Market Analysis (2019–2032)
14. Dysmenorrhea Market Access and Reimbursement of Therapies
15. Dysmenorrhea Market Drivers
16. Dysmenorrhea Market Barriers
17. Dysmenorrhea Appendix
18. Dysmenorrhea Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Dysmenorrhea treatment, visit @ Dysmenorrhea Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis